You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Programming Metabolically Fit TILs for Immunotherapy

    SBC: LIPO-IMMUNO TECH LLC            Topic: NCI

    ABSTRACT Advances in molecular biology and genetic engineering have led to the design and use of modified T cells recognize tumors to achieve significant tumor control upon adoptive cell transfer (ACT) to patients. These T cells are either transduced with tumor antigen reactive T cell receptors (TCR), or chimeric antigen receptors (CARs). Recently, a surge in studies with neo-antigen reactive T ce ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. A Novel Waveguide to Enable MAS-DNP-NMR in Standard-bore High-field Magnets

    SBC: DOTY SCIENTIFIC, INC.            Topic: 400

    A Novel Waveguide to Enable MAS-DNP-NMR in Standard-bore High-field Magnets Abstract The critical importance of solid-state NMR (ssNMR) was recently demonstrated by, after nearly two decades of intense efforts, yielding the first atomic-resolution structures of the A?40 and A?42 amyloid fibrils that play a crucial role in Alzheimer’s Disease (AD). Key to that structure determination was a techni ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. XVIR-110 an ultra-long-acting INSTI for HIV pre-exposure prophylaxis in IND-enabling studies

    SBC: EXAVIR THERAPEUTICS INC.            Topic: NIAID

    PROJECT SUMMARY While there are now successful treatment regimens and prevention strategies for people living with HIV/AIDS, the HIV pandemic remains a public health crisis in the United States and worldwide, with nearly 40,000 new infections each year in the US alone. To prevent the spread of HIV in vulnerable populations, the US Preventive Services Task Force has recommended HIV pre-exposure pro ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. AGR2-superantigen vaccine conjugate for the treatment of pancreaticductal adenocarcinoma

    SBC: LEUKOGENE THERAPEUTICS INC            Topic: 101

    Project Summary/Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest forms of cancer. Poor survival rates are largelydue to the late stage at which PDAC is diagnosed and a lack of effective targeted therapies. While the field ofimmunotherapy has significantly increased overall survival in some malignancies, they have not translated toPDAC. The long-term goal of this research pr ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. New approaches to kidney banking through nature-inspired high sub-zero preservation strategies

    SBC: EXPANSE BIO LLC            Topic: 400

    ABSTRACT The kidney transplant waitlist comprises 83% of the U.S. organ transplant waitlist. Yet, for every 5 patients who die or become too sick for transplantation, 3 kidneys are discarded. Organ preservation quality is linked to graft lifespan with kidneys having only 50% graft survival after 10 years. Extending preservation to a week, or longer, would enable nationwide (theoretically global) d ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Affordable sialoglycans and associated reagents for expanded chemoenzymatic production

    SBC: Integrated Micro-Chromatography Systems, Inc.            Topic: 300

    Project Summary Sialoglycans are sialic acid-containing oligosaccharides that play important biological roles in human biology and pathology and are indispensable molecular probes for research related to bacterial and viral infection, cancer metastasis, immune regulation, etc. The multifaceted functions of sialoglycans in human milk are also being explored. Nevertheless, sialoglycan-related resear ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  7. CDK2 inhibitors for protecting hearing loss

    SBC: TING THERAPEUTICS LLC            Topic: NIDCD

    CDK2 inhibitors for protecting hearing loss Ting Therapeutics LLC is a pharmaceutical company developing drugs to prevent and treat hearing loss. Cisplatin is one of the most widely used drugs to treat cancers. However cisplatin anticancer therapy causes high frequency hearing loss in 40-60% of the patients. To date, no drugs have been approved by the Food and Drug Administration for protection fr ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Development of an Innovative Material for Transcatheter Peripheral Embolization

    SBC: Obsidio, Inc.            Topic: NHLBI

    PROJECT SUMMARY Hemorrhage and uncontrolled bleeding are a leading cause of death, and when not fatal can result in adverse health outcomes with long term negative consequences including organ damage or failure, and coma. Uncontrolled bleeding can arise from a variety of diseases, traumatic injuries, and health conditions, such as atrial fibrillation, which afflicts over 2.6M people in the United ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Preclinical evaluation of an otoprotectant TT002

    SBC: TING THERAPEUTICS LLC            Topic: NIDCD

    Project Summary Ting Therapeutics LLC is a pharmaceutical company developing drugs to prevent and treat hearing loss. Cisplatin is one of the most widely used drugs to treat cancers. However, cisplatin therapy causes hearing loss in 40-60% of the patients. To date, no drugs have been approved by the Food and Drug Administration for protection from cisplatin-induced hearing loss (CIHL). Most candid ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  10. Ototoxicity of modified aminoglycosides

    SBC: NUBAD LLC            Topic: NIAID

    PROJECT SUMMARY Aminoglycosides are one of the cheapest and well-known antibiotics in clinical use for over 70 years, but one of the major limitations in their use is their ototoxicity. Although new generations of antibiotics have emerged in the last decades, aminoglycoside antibiotics maintain a leading role in treatment of acute infections and for specific indications such as tuberculosis or the ...

    SBIR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government